Sold Amazon at 3x gains in 2014 because I hated the Fire Phone. Turns out it was the worst investment decision ever — the stock became a 14-bagger while I sat on the sidelines.
The hard lesson? Don’t underestimate founder-led companies betting on innovation, even when they swing and miss.
Just made the same mistake again with TransMedics (TMDX) — bought it, then panicked when they acquired an aviation company (thought it’d destroy margins). Halved my position out of fear.
But I gave it time instead of selling. CEO Waleed Hassanein’s vision: build a nationwide logistics network to actually move organs efficiently. Sounds wild, but it worked.
Fast forward: stock tripled from 2023 lows. Transplant revenue up 32%, logistics up 35%. The aviation unit now handles 78% of transplants. Margins didn’t tank like I feared — they actually improved.
Company’s targeting 10,000 transplants in a few years (vs ~3,000 now). Kidneys and international markets are next.
The real play? Stop betting against founder-led companies that swing big. Their “bad” ideas often become billion-dollar businesses.
Warren Buffett said it best: learn from your mistakes, but it’s better to learn from other people’s.
Keeping this one and adding more.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
The Lesson That Cost Me Millions (But Made Me Rich)
Sold Amazon at 3x gains in 2014 because I hated the Fire Phone. Turns out it was the worst investment decision ever — the stock became a 14-bagger while I sat on the sidelines.
The hard lesson? Don’t underestimate founder-led companies betting on innovation, even when they swing and miss.
Just made the same mistake again with TransMedics (TMDX) — bought it, then panicked when they acquired an aviation company (thought it’d destroy margins). Halved my position out of fear.
But I gave it time instead of selling. CEO Waleed Hassanein’s vision: build a nationwide logistics network to actually move organs efficiently. Sounds wild, but it worked.
Fast forward: stock tripled from 2023 lows. Transplant revenue up 32%, logistics up 35%. The aviation unit now handles 78% of transplants. Margins didn’t tank like I feared — they actually improved.
Company’s targeting 10,000 transplants in a few years (vs ~3,000 now). Kidneys and international markets are next.
The real play? Stop betting against founder-led companies that swing big. Their “bad” ideas often become billion-dollar businesses.
Warren Buffett said it best: learn from your mistakes, but it’s better to learn from other people’s.
Keeping this one and adding more.